Cargando…

Connexin 30 deficiency attenuates A2 astrocyte responses and induces severe neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride Parkinson’s disease animal model

BACKGROUND: The first pathology observed in Parkinson’s disease (PD) is ‘dying back’ of striatal dopaminergic (DA) terminals. Connexin (Cx)30, an astrocytic gap junction protein, is upregulated in the striatum in PD, but its roles in neurodegeneration remain elusive. We investigated Cx30 function in...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujita, Atsushi, Yamaguchi, Hiroo, Yamasaki, Ryo, Cui, Yiwen, Matsuoka, Yuta, Yamada, Ken-ichi, Kira, Jun-ichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090688/
https://www.ncbi.nlm.nih.gov/pubmed/30103794
http://dx.doi.org/10.1186/s12974-018-1251-0
_version_ 1783347236000759808
author Fujita, Atsushi
Yamaguchi, Hiroo
Yamasaki, Ryo
Cui, Yiwen
Matsuoka, Yuta
Yamada, Ken-ichi
Kira, Jun-ichi
author_facet Fujita, Atsushi
Yamaguchi, Hiroo
Yamasaki, Ryo
Cui, Yiwen
Matsuoka, Yuta
Yamada, Ken-ichi
Kira, Jun-ichi
author_sort Fujita, Atsushi
collection PubMed
description BACKGROUND: The first pathology observed in Parkinson’s disease (PD) is ‘dying back’ of striatal dopaminergic (DA) terminals. Connexin (Cx)30, an astrocytic gap junction protein, is upregulated in the striatum in PD, but its roles in neurodegeneration remain elusive. We investigated Cx30 function in an acute PD model by administering 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to wild-type (WT) and Cx30 knockout (KO) mice. METHODS: On days 1 and 7 after MPTP administration, we evaluated changes in astrocytic Cx30, Cx43, glial fibrillary acidic protein, and ionised calcium-binding adapter molecule 1 expression by immunostaining and biochemical analysis. Loss of DA neurons was evaluated by tyrosine hydroxylase immunostaining. Gene expression was analysed using A1, A2, pan-reactive astrocyte microarray gene sets, and M1, M2, and M1/M2 mixed microglial microarray gene sets. Real-time PCR and in situ hybridisation were performed to evaluate glial cell-derived neurotrophic factor (Gdnf) and S100a10 expression. Striatal GDNF protein levels were determined by enzyme-linked immunosorbent assay. RESULTS: MPTP treatment induced upregulation of Cx30 and Cx43 levels in the striatum of WT and KO mice. DA neuron loss was accelerated in Cx30 KO compared with WT mice after MPTP administration, despite no change in the striatal concentration of methyl-4-phenylpyridinium(+). Astrogliosis in the striatum of Cx30 KO mice was attenuated by MPTP, whereas microglial activation was unaffected. Microarrays of the striatum showed reduced expression of pan-reactive and A2 astrocyte genes after MPTP treatment in Cx30 KO compared with WT mice, while M1, M2, and M1/M2 mixed microglial gene expression did not change. MPTP reduced the number of striatal astrocytes co-expressing Gdnf mRNA and S100β protein or S100a10 mRNA and S100β protein and also reduced the level of GDNF in the striatum of Cx30 KO compared with WT mice. CONCLUSIONS: These findings indicate that Cx30 plays critical roles in astrocyte neuroprotection in an MPTP PD model. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12974-018-1251-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6090688
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-60906882018-08-17 Connexin 30 deficiency attenuates A2 astrocyte responses and induces severe neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride Parkinson’s disease animal model Fujita, Atsushi Yamaguchi, Hiroo Yamasaki, Ryo Cui, Yiwen Matsuoka, Yuta Yamada, Ken-ichi Kira, Jun-ichi J Neuroinflammation Research BACKGROUND: The first pathology observed in Parkinson’s disease (PD) is ‘dying back’ of striatal dopaminergic (DA) terminals. Connexin (Cx)30, an astrocytic gap junction protein, is upregulated in the striatum in PD, but its roles in neurodegeneration remain elusive. We investigated Cx30 function in an acute PD model by administering 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to wild-type (WT) and Cx30 knockout (KO) mice. METHODS: On days 1 and 7 after MPTP administration, we evaluated changes in astrocytic Cx30, Cx43, glial fibrillary acidic protein, and ionised calcium-binding adapter molecule 1 expression by immunostaining and biochemical analysis. Loss of DA neurons was evaluated by tyrosine hydroxylase immunostaining. Gene expression was analysed using A1, A2, pan-reactive astrocyte microarray gene sets, and M1, M2, and M1/M2 mixed microglial microarray gene sets. Real-time PCR and in situ hybridisation were performed to evaluate glial cell-derived neurotrophic factor (Gdnf) and S100a10 expression. Striatal GDNF protein levels were determined by enzyme-linked immunosorbent assay. RESULTS: MPTP treatment induced upregulation of Cx30 and Cx43 levels in the striatum of WT and KO mice. DA neuron loss was accelerated in Cx30 KO compared with WT mice after MPTP administration, despite no change in the striatal concentration of methyl-4-phenylpyridinium(+). Astrogliosis in the striatum of Cx30 KO mice was attenuated by MPTP, whereas microglial activation was unaffected. Microarrays of the striatum showed reduced expression of pan-reactive and A2 astrocyte genes after MPTP treatment in Cx30 KO compared with WT mice, while M1, M2, and M1/M2 mixed microglial gene expression did not change. MPTP reduced the number of striatal astrocytes co-expressing Gdnf mRNA and S100β protein or S100a10 mRNA and S100β protein and also reduced the level of GDNF in the striatum of Cx30 KO compared with WT mice. CONCLUSIONS: These findings indicate that Cx30 plays critical roles in astrocyte neuroprotection in an MPTP PD model. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12974-018-1251-0) contains supplementary material, which is available to authorized users. BioMed Central 2018-08-13 /pmc/articles/PMC6090688/ /pubmed/30103794 http://dx.doi.org/10.1186/s12974-018-1251-0 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Fujita, Atsushi
Yamaguchi, Hiroo
Yamasaki, Ryo
Cui, Yiwen
Matsuoka, Yuta
Yamada, Ken-ichi
Kira, Jun-ichi
Connexin 30 deficiency attenuates A2 astrocyte responses and induces severe neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride Parkinson’s disease animal model
title Connexin 30 deficiency attenuates A2 astrocyte responses and induces severe neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride Parkinson’s disease animal model
title_full Connexin 30 deficiency attenuates A2 astrocyte responses and induces severe neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride Parkinson’s disease animal model
title_fullStr Connexin 30 deficiency attenuates A2 astrocyte responses and induces severe neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride Parkinson’s disease animal model
title_full_unstemmed Connexin 30 deficiency attenuates A2 astrocyte responses and induces severe neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride Parkinson’s disease animal model
title_short Connexin 30 deficiency attenuates A2 astrocyte responses and induces severe neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride Parkinson’s disease animal model
title_sort connexin 30 deficiency attenuates a2 astrocyte responses and induces severe neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride parkinson’s disease animal model
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090688/
https://www.ncbi.nlm.nih.gov/pubmed/30103794
http://dx.doi.org/10.1186/s12974-018-1251-0
work_keys_str_mv AT fujitaatsushi connexin30deficiencyattenuatesa2astrocyteresponsesandinducessevereneurodegenerationina1methyl4phenyl1236tetrahydropyridinehydrochlorideparkinsonsdiseaseanimalmodel
AT yamaguchihiroo connexin30deficiencyattenuatesa2astrocyteresponsesandinducessevereneurodegenerationina1methyl4phenyl1236tetrahydropyridinehydrochlorideparkinsonsdiseaseanimalmodel
AT yamasakiryo connexin30deficiencyattenuatesa2astrocyteresponsesandinducessevereneurodegenerationina1methyl4phenyl1236tetrahydropyridinehydrochlorideparkinsonsdiseaseanimalmodel
AT cuiyiwen connexin30deficiencyattenuatesa2astrocyteresponsesandinducessevereneurodegenerationina1methyl4phenyl1236tetrahydropyridinehydrochlorideparkinsonsdiseaseanimalmodel
AT matsuokayuta connexin30deficiencyattenuatesa2astrocyteresponsesandinducessevereneurodegenerationina1methyl4phenyl1236tetrahydropyridinehydrochlorideparkinsonsdiseaseanimalmodel
AT yamadakenichi connexin30deficiencyattenuatesa2astrocyteresponsesandinducessevereneurodegenerationina1methyl4phenyl1236tetrahydropyridinehydrochlorideparkinsonsdiseaseanimalmodel
AT kirajunichi connexin30deficiencyattenuatesa2astrocyteresponsesandinducessevereneurodegenerationina1methyl4phenyl1236tetrahydropyridinehydrochlorideparkinsonsdiseaseanimalmodel